Nurse Practitioner, Family · Hartford, CT
NPI
1417480229
Since 2017
Specialty
Nurse Practitioner, Family
Code 363LF0000X
Group practices
1
Medicare group memberships
Hospitals
1
Hospital affiliations
500 Albany Ave
Hartford, CT, 06120
Phone (860) 249-9625
Groups this clinician bills Medicare through
Medicare paid, 2024
$9,050
204 services
Medicare patients, 2024
65
Average age 65
Drug cost, 2024
$2.4M
4,395 prescriptions
Company payments, 2025
$1,514
From 12 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Jaime Kweon was code 99214 (office e&m - established), 90 times for 48 patients. In total Jaime Kweon billed 204 services in 7 codes, and Medicare paid $9,050.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2017-04-07.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Facility | 90 | 48 | $59.64 | $5,368 |
| 95251 Test - Miscellaneous | Facility | 58 | 35 | $22.64 | $1,313 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Facility | 26 | 26 | $11.51 | $299 |
By year: 2022 $9,405 for 184 services; 2023 $8,551 for 182 services; 2024 $9,050 for 204 services.
Medicare prescription drug claims, 2024
In 2024, the drug Jaime Kweon prescribed most often to Medicare patients was Ozempic (Semaglutide), with 451 prescriptions and refills. In total Jaime Kweon wrote 4,395 Medicare prescriptions that cost $2.4M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Ozempic Semaglutide | 451 | 543 | 104 | $489K |
| Mounjaro Tirzepatide | 393 | 412 | 96 | $449K |
| Lantus Solostar Insulin Glargine,hum.Rec.Anlog | 273 | 649 | 106 | $27K |
| Trulicity Dulaglutide | 249 | 280 | 51 | $278K |
| Insulin Lispro Kwikpen U-100 Insulin Lispro | 227 | 422 | 81 | $46K |
| Nano 2nd Gen Pen Needle Pen Needle, Diabetic | 208 | 455 | 95 | $20K |
| Jardiance Empagliflozin | 182 | 338 | 53 | $199K |
| Metformin Hcl Generic | 178 | 350 | 52 | $1,041 |
| Tresiba Flextouch U-200 Insulin Degludec | 175 | 311 | 47 | $126K |
| Ultra-Fine Nano Pen Needle Pen Needle, Diabetic | 143 | 265 | 54 | $13K |
| Metformin Hcl Er Metformin Hcl | 138 | 317 | 53 | $1,694 |
| Tresiba Flextouch U-100 Insulin Degludec | 133 | 311 | 51 | $70K |
| Novolog Flexpen Insulin Aspart | 116 | 239 | 45 | $21K |
| Tradjenta Linagliptin | 115 | 204 | 32 | $105K |
| Humalog Kwikpen U-100 Insulin Lispro | 114 | 222 | 46 | $23K |
Brand drugs: 3,043 claims; generic drugs: 600 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Jaime Kweon $1,514 ($1,514 in general payments such as food, travel and fees) from 12 companies. The largest payer was Novo Nordisk Inc with $553.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.